WASHINGTON — Hopes for a new, moxifloxacin-containing tuberculosis (TB) treatment that might have shortened therapy from 6 to 4 months suffered a setback today with the results of REMoxTB study, one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results